Anti-Human KLRC1 Recombinant Antibody (TAB-437CQ) (CAT#: TAB-437CQ)

Battin, Claire, et al. "NKG2A-checkpoint inhibition and its blockade critically depends on peptides presented by its ligand HLA-E." Immunology 166.4 (2022): 507-521. https://doi.org/10.1111/imm.13515

This study investigates the dependence of NKG2A-checkpoint inhibition and its blockade on peptides presented by its ligand HLA-E. Researchers evaluated how different HLA-E-bound peptides impact the inhibitory signaling of NKG2A and the efficacy of monalizumab, a novel immune checkpoint inhibitor (ICI) targeting NKG2A. They found that various peptides derived from the leader sequences of classical MHC class I molecules and the non-classical class I paralogue HLA-G mediate different levels of NKG2A inhibition. The study shows that monalizumab's effectiveness in enhancing NK and CD8+ T cell responses depends significantly on the specific peptide presented by HLA-E, with peptides from HLA-G being less effectively blocked compared to those from HLA-A, HLA-B, and HLA-C.
At Creative Biolabs, we contributed to this critical research by supplying the therapeutic NKG2A antibody monalizumab (Cat#: TAB-437CQ) used in the study to assess its binding and blocking capacities. Our product was essential in demonstrating that monalizumab's efficiency in blocking NKG2A-mediated inhibition varies with different HLA-E-bound peptides. This research highlights the importance of peptide-HLA-E interactions in determining the success of NKG2A-targeted immunotherapies, showcasing our commitment to advancing cancer immunotherapy research and developing innovative therapeutic solutions.

Choi, Seong Jin, et al. "KIR+ CD8+ and NKG2A+ CD8+ T cells are distinct innate-like populations in humans." Cell Reports 42.3 (2023). https://doi.org/10.1016/j.celrep.2023.112236

This study explores the heterogeneity among human KIR+CD8+ and NKG2A+CD8+ T cells, identifying them as distinct innate-like populations with different cytokine responsiveness. The research demonstrates that KIR+CD8+ T cells exhibit IL-15-induced NK-like cytotoxicity, while NKG2A+CD8+ T cells show IL-12/IL-18-induced IFN-gamma production. It was observed that KIR+CD8+ T cells are more terminally differentiated and replicative senescent compared to NKG2A+CD8+ T cells, which are more responsive to IL-12 and IL-18 due to the high expression of these receptors induced by the transcription factor PLZF.
At Creative Biolabs, we provided essential reagents for this study, including the anti-NKG2A antibody (Cat#: TAB-437CQ) and the IgG4 isotype control (Cat# MOB-0408ZL) used in the flow cytometry analyses. Our products were crucial in identifying the distinct functional roles and cytokine responses of these T cell subsets. This research underscores the importance of understanding the diverse functions of T cell populations in developing targeted immunotherapies, highlighting our commitment to advancing immunological research and innovative therapeutic solutions.